

References

- Abdel-Ilah, L., Veljović, E., Gurbeta, L., & Badnjević, A. (2017). Applications of QSAR study in drug design. *Int J Eng Res Technol*, 6(06), 582-587.
- Ahmed, M. M., Amin, A. M., & Rahman, N. A. (2024). In silico docking and ADMET prediction of phytochemicals as antimalarial agents targeting DHFR. *BMC Chemistry*, 18(1), Article 55. <https://doi.org/10.1186/s13065-024-01355-4>
- Alves-Rosa, M. F., Tayler, N. M., Dorta, D., Coronado, L. M., & Spadafora, C. (2024). P. falciparum Invasion and Erythrocyte Aging. *Cells*, 13(4), 334.
- Aurora, Y., Tarigan, I. P. N., Suryanto, N. M. M., Santosa, P., Pricillia, V., & Parikesit, A. A. (2022). Identification of flavonoids of Kalanchoe Pinnata as candidate drugs for COVID-19 gamma-variant treatment. *Malaysian Journal of Fundamental and Applied Sciences*, 18(6), 630-643.
- Baggish, A. L., & Hill, D. R. (2002). Antiparasitic agent atovaquone. *Antimicrobial agents and chemotherapy*, 46(5), 1163-1173.
- Das, J., & Rahman, G. M. (2014). C1 domains: structure and ligand-binding properties. *Chemical reviews*, 114(24), 12108-12131.
- Davis, T. M., Hung, T. Y., Sim, I. K., Karunajeewa, H. A., & Ilett, K. F. (2005). Piperaquine: a resurgent antimalarial drug. *Drugs*, 65, 75-87.
- Difa, C. A., Eze, C. K., Iyaji, R. F., Cosmas, S., & Durojaye, A. O. (2018). In-Silico pharmacokinetics study on the inhibitory potentials of the C= O derivative of gedunin and pyrimethamine against the Plasmodium falciparum dihydrofolate reductase. *Ciência*, 4, 137-142.
- Kogan, F., & Kogan, F. (2020). Malaria burden. *Remote Sensing for Malaria: Monitoring and Predicting Malaria from Operational Satellites*, 15-41.
- Llanos-Cuentas, A., Manrique, P., Rosas-Aguirre, A., Herrera, S., & Hsiang, M. S. (2022). Tafenoquine for the treatment of Plasmodium vivax malaria. *Expert Opinion on Pharmacotherapy*, 23(7), 759-768.

- Lorell, J., Gautama, N. R. P., Tanzil, T. S., Subagja, M., & Parikesit, A. A. (2025). In silico study of RNA polymerase inhibitor drugs for Rift Valley fever virus using RdRp protein as the target. *Journal of Pharmacy & Pharmacognosy Research*, 13(1), 1–15. https://doi.org/10.56499/jppres24.1967_13.1.1
- Maier, A. G., Matuschewski, K., Zhang, M., & Rug, M. (2019). Plasmodium falciparum. *Trends in parasitology*, 35(6), 481-482.
- Marchi, E., Mangone, M., Zullo, K., & O'Connor, O. A. (2013). Pralatrexate pharmacology and clinical development. *Clinical Cancer Research*, 19(24), 6657-6661.
- Matthews, D. C., & Appelbaum, F. R. (2004). Radioimmunotherapy and hematopoietic cell transplantation. *Thomas' hematopoietic cell transplantation*, 198-208.
- Meisel, R., Bardenheuer, W., Strehblow, C., Sorg, U. R., Elmaagacli, A., Seeber, S., ... & Moritz, T. (2003). Efficient protection from methotrexate toxicity and selection of transduced human hematopoietic cells following gene transfer of dihydrofolate reductase mutants. *Experimental hematology*, 31(12), 1215-1222.
- Musa, K. A. (2021). *Investigation of the Binding Characteristics of Anti-Malarial Drugs, Mefloquine, Lumefantrine and Pyrimethamine to Human Serum Albumin Using Spectroscopic and Molecular Docking Methods* (Doctoral dissertation, University of Malaya (Malaysia)).
- Niazi, S. K., & Mariam, Z. (2023). Computer-aided drug design and drug discovery: a prospective analysis. *Pharmaceuticals*, 17(1), 22.
- Oranusi, S. U., Mameh, E. O., Oyegbade, S. A., Balogun, D. O., & Aririguzoh, V. G. O. (2024). Inhibitors of Protein Targets of Plasmodium falciparum. *Journal of Pure & Applied Microbiology*, 18(4).
- Parikesit, A. A., & Nurdiansyah, R. (2021). Natural products repurposing of the H5N1-based lead compounds for the most fit inhibitors against 3C-like protease of SARS-CoV-2. *Journal of Pharmacy & Pharmacognosy Research*, 9(5), 730–745. https://doi.org/10.56499/jppres21.1080_9.5.730

- Putra, H. D., Yuliani, R., & Puspitasari, N. (2024). Antiviral potential of methotrexate against DHFR protein: An in silico approach. *Antibiotics*, 13(6), 479. <https://doi.org/10.3390/antibiotics13060479>
- Rao, A. S., & Tapale, S. R. (2013). A study on dihydrofolate reductase and its inhibitors: A review. *International Journal of Pharmaceutical Sciences and Research*, 4(7), 2535.
- Sato, S. (2021). Plasmodium—a brief introduction to the parasites causing human malaria and their basic biology. *Journal of physiological anthropology*, 40(1), 1.
- Science for the Days. (2021, March). Molecular docking. *Science for the Days*. <https://scienceforthedays.blogspot.com/2021/03/molecular-docking.html>
- Shibeshi, M. A., Kifle, Z. D., & Atnafie, S. A. (2020). Antimalarial drug resistance and novel targets for antimalarial drug discovery. *Infection and drug resistance*, 4047-4060.
- Trujillo, M., Donald, R. G., Roos, D. S., Greene, P. J., & Santi, D. V. (1996). Heterologous Expression and Characterization of the Bifunctional Dihydrofolate Reductase–Thymidylate Synthase Enzyme of *Toxoplasma gondii*. *Biochemistry*, 35(20), 6366-6374.
- Vásquez, J. R., Goozé, L., Kim, K., Gut, J., Petersen, C., & Nelson, R. G. (1996). Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of *Cryptosporidium parvum*. *Molecular and biochemical parasitology*, 79(2), 153-165.
- Wang, K., Huang, Y., Wang, Y., You, Q., & Wang, L. (2024). Recent advances from computer-aided drug design to artificial intelligence drug design. *RSC Medicinal Chemistry*, 15(12), 3978-4000.
- Yu, W., & MacKerell Jr, A. D. (2016). Computer-aided drug design methods. In *Antibiotics: methods and protocols* (pp. 85-106). New York, NY: Springer New York.
- Zekar, L., & Sharman, T. (2023). *Plasmodium falciparum malaria*. In *StatPearls [Internet]*. StatPearls Publishing.